Cargando…

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome

Sezary Syndrome (SS) is a rare leukemic variant of primary cutaneous T-cell lymphoma. Relapsed or refractory disease is generally considered incurable by conventional therapeutic approaches, although durable responses can be achieved with novel monoclonal antibodies. Allogeneic hematopoietic stem ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franke, Georg-Nikolaus, Dumann, Konstantin, Jentzsch, Madlen, Monecke, Astrid, Doehring, Christine, Nehring-Vucinic, Claudia, Schwind, Sebastian, Niederwieser, Dietger, Platzbecker, Uwe, Ziemer, Mirjana, Vucinic, Vladan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695846/ https://www.ncbi.nlm.nih.gov/pubmed/34956873 http://dx.doi.org/10.3389/fonc.2021.749691

Ejemplares similares

A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
por: Backhaus, Donata, et al.
Publicado: (2022)

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation
por: Brauer, Dominic, et al.
Publicado: (2021)

P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
por: Franke, Georg-Nikolaus, et al.
Publicado: (2023)

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
por: Hell, Saskia, et al.
Publicado: (2022)

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
por: Gerhardt, Kristin, et al.
Publicado: (2021)

The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia
por: Vucinic, Vladan, et al.
Publicado: (2021)

Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2023)

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation with the CD34(+)/CD38(-) population
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients
por: Jentzsch, Madlen, et al.
Publicado: (2017)

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
por: Bill, Marius, et al.
Publicado: (2022)

P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
por: Bischof, Lara, et al.
Publicado: (2023)

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
por: Backhaus, Donata, et al.
Publicado: (2021)

Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia
por: Jentzsch, Madlen, et al.
Publicado: (2019)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023)

Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2022)

Case Report: Allogeneic Stem Cell Transplantation Following Induction With CPX-351 in Patients With Acute Myeloid Leukemia Is Feasible
por: Vucinic, Vladan, et al.
Publicado: (2020)

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Brentuximab Vedotin
Publicado: (2012)

Case Report: Large Granular Lymphocyte Leukemia (LGLL)—A Case Series of Challenging Presentations
por: Pflug, Natali, et al.
Publicado: (2022)

Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma
por: Kubasch, Anne Sophie, et al.
Publicado: (2020)

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML
por: Jentzsch, Madlen, et al.
Publicado: (2020)

P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
por: Jentzsch, M., et al.
Publicado: (2022)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

P1313: PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH
por: Jentzsch, M., et al.
Publicado: (2022)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Brentuximab vedotin: axonal microtubule's Apollyon
por: Mariotto, S, et al.
Publicado: (2015)

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
por: Wang, Song-Yau, et al.
Publicado: (2022)

P1381: EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS
por: Ussmann, J., et al.
Publicado: (2022)

Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy
por: Georgi, Thomas Walter, et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Brentuximab vedotin: clinical updates and practical guidance
por: Yi, Jun Ho, et al.
Publicado: (2017)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_78klvarmukqtugkee4271fl4er